Newborn screening for sickle cell disease in Mozambique
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is testing a new way to screen all newborns for sickle cell disease in Mozambique. It aims to find babies with the condition early so they can get the right care from the start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be between birth and 6 months old.
- Your baby must be born or seen at a participating health center in Mozambique.
- Your baby must not have had a blood transfusion in the last 3 months.
- Healthcare workers or experts who help run these health centers can also take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new computer system to help hospitals quickly identify babies with sickle cell disease (an inherited blood disorder) right after birth or at early health visits. Finding sickle cell disease early helps prevent serious health problems and saves lives.
This study tests a new way to screen babies for sickle cell disease at the point of care. It aims to make screening faster and easier for families and health workers.
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
This study collects blood samples from up to 1 million people in Uganda to learn more about sickle cell disease. It helps doctors understand how common it is and how to better care for those affected.
This study helps connect adults with sickle cell disease who haven't seen a specialist in over a year back into care. It tests a program designed to make it easier to get regular medical support and improve your health.
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.